Cannabigerol (CBG) is a minor cannabinoid found in most cannabis varieties at low concentrations — typically under 1% in mature flower. Despite its low abundance, CBG holds a uniquely foundational role in cannabis biochemistry: its acid form, CBGA (cannabigerolic acid), is the enzymatic precursor from which all major cannabinoids are biosynthesized.
As the cannabis plant matures, CBGA is converted by specific plant enzymes into THCA, CBDA, and CBCA (the acid precursors of THC, CBD, and CBC respectively). Any CBGA that remains unconverted at harvest is subsequently decarboxylated to CBG. This is why mature cannabis plants are so low in CBG — most of it has already been converted into other cannabinoids. Cultivators who want to maximize CBG content must harvest plants at an earlier stage, typically 6–8 weeks into flowering before the enzymatic conversion is complete.
The biosynthetic pathway begins with two precursors: geranyl pyrophosphate (GPP) and olivetolic acid. The enzyme CBGA synthase combines these into CBGA. From CBGA, three plant-specific enzymes then branch the pathway:
The ratio of these enzymes, genetically determined by the plant’s chemotype, dictates the cannabinoid profile of the final product. A plant with dominant THCA synthase activity produces a high-THC chemotype (Type I). A plant with dominant CBDA synthase activity produces a high-CBD chemotype (Type II). Plants with balanced enzyme expression produce mixed profiles (Type III). High-CBG cultivars are bred to minimize all three conversion enzymes, allowing CBGA to accumulate without conversion.
CBG’s pharmacological profile is distinct from CBD in several important ways. While CBD acts primarily as a modulator (indirect activity) at cannabinoid receptors, CBG acts as a partial agonist at both CB1 and CB2 receptors. This means CBG directly activates these receptors, though with lower efficacy than THC.
At CB1 receptors: CBG’s partial agonism contributes to appetite stimulation (a property shared with THC but not CBD), mild analgesic effects, and potentially neuroprotective actions. At CB2 receptors: CBG’s activation contributes to anti-inflammatory and immunomodulatory effects, particularly in the gut and peripheral tissues.
CBG also interacts with the endocannabinoid system through non-receptor mechanisms: it inhibits the reuptake of anandamide (the endocannabinoid associated with mood and appetite), potentially amplifying anandamide’s effects at its natural receptors. This anandamide-enhancing property may contribute to CBG’s reported mood-lifting effects.
Additionally, CBG is a potent agonist at alpha-2 adrenergic receptors (potentially contributing to blood pressure reduction) and a moderate TRPV1 receptor activator (involved in pain and temperature regulation). This multi-receptor profile makes CBG pharmacologically interesting for several therapeutic applications.
| Property | CBG | CBD |
|---|---|---|
| Psychoactivity | None at typical doses | None at any dose |
| CB1 receptor action | Partial agonist (direct binding) | Negative allosteric modulator (indirect) |
| CB2 receptor action | Partial agonist | Partial agonist/modulator |
| Appetite effect | Stimulates appetite | Neutral to mild suppression |
| Antibacterial | Strong (MRSA data) | Moderate |
| Neuroprotection | Strong preclinical evidence | Moderate preclinical evidence |
| Anti-anxiety | Moderate (preclinical) | Strong (clinical evidence) |
| Anti-epileptic | Early research | FDA-approved (Epidiolex) |
| Availability | Limited, more expensive | Widely available, affordable |
| Clinical trial evidence | Mostly preclinical | Significant clinical data |
A 2015 study published in Neurotherapeutics found CBG showed neuroprotective properties in a mouse model of Huntington’s disease, significantly reducing striatal neuronal loss. The proposed mechanism involves CBG’s antioxidant properties, PPAR-gamma activation, and its ability to reduce neuroinflammation. Preclinical studies have also explored CBG’s potential in Parkinson’s disease and ALS models, with promising but preliminary results.
A 2020 study in ACS Infectious Diseases (McMaster University) tested five major cannabinoids against antibiotic-resistant bacteria and found CBG was the most potent, demonstrating activity against MRSA (methicillin-resistant Staphylococcus aureus) that outperformed CBD, CBC, THC, and CBN. CBG was able to disrupt established MRSA biofilms — one of the main resistance mechanisms — and showed synergistic effects when combined with conventional antibiotics. While not yet in clinical use, this is a genuinely exciting finding for post-antibiotic medicine.
A 2013 study in Biochemical Pharmacology found CBG significantly reduced inflammation and oxidative stress in a mouse model of inflammatory bowel disease (IBD). CBG reduced nitric oxide production in intestinal macrophages, reduced reactive oxygen species, and downregulated pro-inflammatory markers. The gut has a particularly high density of CB2 receptors, which may explain CBG’s affinity for GI applications.
Preclinical studies have explored CBG’s potential in colorectal cancer. A 2014 study found CBG inhibited the growth of colon carcinoma cells and reduced tumor formation in a mouse model. The mechanism appears to involve CB1 and CB2 receptor activation, PPAR-gamma agonism, and inhibition of TRPV1 receptors. These findings are preclinical and far from clinical application, but represent a meaningful research direction.
| Strain | CBG Content | THC Content | Notes |
|---|---|---|---|
| White CBG | 9–12% | <0.3% | Purpose-bred CBG hemp; white, dense buds |
| Jack Frost CBG | 8–11% | <0.3% | Jack Herer derivative; citrus/pine aroma |
| Sour G | 6–10% | <0.3% | CBG-dominant phenotype of Sour Diesel lineage |
| Super Glue CBG | 5–8% | <0.3% | High-yield CBG strain, earthy notes |
| Lemon Cream Diesel CBG | 7–10% | <0.3% | High terpene content alongside CBG, citrus-forward |
CBG isolate is a purified crystalline compound containing 98%+ CBG with no other cannabinoids or terpenes. It provides the most precise dosing and is free from any trace THC. However, like all isolates, it may lack the entourage effect benefits of whole-plant or broad-spectrum formulations.
Full-spectrum CBG oil contains CBG alongside trace amounts of other cannabinoids (including THC — usually under 0.3% in hemp-derived products), terpenes, and flavonoids. The entourage effect hypothesis suggests these compounds work synergistically, potentially amplifying CBG’s benefits. For most therapeutic applications, a broad-spectrum or full-spectrum formulation is likely preferable to isolate.
Ann Karim
Cannabis Science & Wellness Writer — ZenWeedGuide
Ann covers emerging cannabinoid science including CBG, CBN, and CBC, translating preclinical research into consumer-relevant guidance with appropriate caveats about evidence levels.
